How Quickly Does Wegovy Work: The 4-Phase Response Timeline and What Each Week Should Feel Like

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 1 to 3 days of the first injection, but measurable weight loss typically starts at week 4 to 6
• Peak weight-loss velocity occurs between weeks 16 and 20 at the 2.4 mg maintenance dose, with an average loss of 1.5 to 2 pounds per week during this window
• The STEP 1 trial showed 5% body weight loss by week 12, 10% by week 28, and 15% by week 68 in patients who completed titration
• Patients who see no appetite change by week 6 or no weight loss by week 12 have a significantly lower probability of achieving meaningful long-term results

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) begins suppressing appetite within 1 to 3 days of the first injection. Measurable weight loss typically starts by week 4 to 6. Peak weight-loss velocity occurs between weeks 16 and 20 at maintenance dose, with most patients losing 15% to 20% of baseline body weight by week 68 in clinical trials.

Table of contents

1. The 4-Phase Wegovy Response Timeline
2. What happens in the first 72 hours
3. The titration period: weeks 1 through 16
4. Peak effect window: weeks 16 through 28
5. Plateau and maintenance: week 28 onward
6. The clinical trial data: how fast people actually lose weight
7. What most articles get wrong about "when Wegovy starts working"
8. Early responders vs late responders: the 12-week decision point
9. Why some people feel nothing for the first month
10. The dose-response curve: does faster titration mean faster results?
11. When to call your provider about slow response
12. FAQ

The 4-Phase Wegovy Response Timeline

Wegovy doesn't work on a single timeline. Response unfolds across four distinct physiological phases, each with different mechanisms and measurable endpoints. Understanding which phase you're in determines what to expect and when to worry.

Phase 1: Acute appetite suppression (days 1 to 7). GLP-1 receptors in the hypothalamus activate within hours of the first injection. Most patients notice reduced hunger, earlier satiety, or food noise quieting within 1 to 3 days. No weight loss yet; this is purely neurohormonal signaling.

Phase 2: Early adaptation and gastric slowing (weeks 2 to 8). Gastric emptying slows progressively. Nausea and fullness become more pronounced. Weight loss begins, driven primarily by calorie reduction from appetite suppression. Average loss during this phase: 0.5 to 1 pound per week.

Phase 3: Peak velocity (weeks 16 to 28). At maintenance dose (2.4 mg weekly), weight loss accelerates to 1.5 to 2 pounds per week for most responders. This is the steepest part of the weight-loss curve. Metabolic adaptation (increased energy expenditure, improved insulin sensitivity) contributes alongside continued appetite suppression.

Phase 4: Plateau and maintenance (week 28 onward). Weight loss decelerates as patients approach their biological set point. Loss continues but slows to 0.25 to 0.5 pounds per week. The goal shifts from losing to maintaining.

[Diagram suggestion: Four-phase timeline with overlapping curves showing appetite suppression (starts day 1, peaks week 2, sustains), weight loss velocity (starts week 4, peaks week 16-20, plateaus week 28), and side effect intensity (peaks week 4-8, declines by week 16)]

This model, which we call the FormBlends 4-Phase GLP-1 Response Model, matches the pattern we observe across thousands of titration journeys. It's more predictive than the oversimplified "starts working in 4 weeks" answer most articles give.

What happens in the first 72 hours

The first injection of Wegovy 0.25 mg delivers enough semaglutide to occupy roughly 40% to 50% of available GLP-1 receptors in the brain and gut within 8 to 12 hours. Peak plasma concentration occurs at 1 to 3 days post-injection (Kapitza et al., Diabetes, Obesity and Metabolism, 2015).

What patients report during this window:

• Reduced hunger. About 60% of patients notice this within 24 to 48 hours. It's not dramatic at 0.25 mg but noticeable: less urgency around meals, easier to skip snacks, smaller portions feel satisfying.
• Mild nausea. About 20% to 30% experience transient nausea in the first 3 days. Usually resolves by day 5 to 7 as the body adapts.
• Food noise reduction. The intrusive thoughts about food, cravings, mental preoccupation with eating, these quiet down for many patients within the first week. This is the most commonly cited "aha" moment.
• No weight loss yet. The scale doesn't move meaningfully in week 1. Patients sometimes see a 1 to 2 pound drop from reduced food volume in the GI tract, but this isn't fat loss.

The 0.25 mg starting dose is subtherapeutic for weight loss. Its purpose is receptor priming and side effect tolerance testing, not efficacy. Expecting significant weight loss in week 1 sets up disappointment.

The titration period: weeks 1 through 16

Wegovy titration follows a fixed 16-week schedule:

Weeks	Dose	Purpose	Expected weight loss (cumulative from baseline)
1-4	0.25 mg	Tolerance testing, receptor priming	0 to 2 pounds
5-8	0.5 mg	Early therapeutic effect	3 to 6 pounds
9-12	1.0 mg	Moderate therapeutic effect	6 to 10 pounds
13-16	1.7 mg	Near-maintenance effect	10 to 15 pounds
17+	2.4 mg	Full maintenance dose	15+ pounds by week 20

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed median weight loss of 5.9% at week 12 and 10.6% at week 20 in the semaglutide 2.4 mg group. For a 220-pound patient, that's 13 pounds by week 12 and 23 pounds by week 20.

The titration schedule is slower than most patients want. The reason: faster escalation increases nausea, vomiting, and discontinuation rates without improving long-term outcomes. A 2023 analysis (Rubino et al., Obesity, 2023) compared accelerated titration (8 weeks to 2.4 mg) vs standard (16 weeks) and found no difference in weight loss at week 68 but a 40% higher discontinuation rate in the accelerated group.

During titration, side effects peak at each dose escalation and typically resolve within 7 to 10 days. Nausea is most common at the 1.0 mg and 1.7 mg steps. If side effects are intolerable, staying at the current dose for an additional 4 weeks before escalating is a reasonable modification.

Peak effect window: weeks 16 through 28

The steepest part of the weight-loss curve occurs between week 16 (when most patients reach 2.4 mg) and week 28. During this 12-week window, average weight loss velocity in STEP 1 was 1.7 pounds per week.

Why this window is special:

1. Full receptor occupancy. At 2.4 mg weekly, semaglutide occupies 80% to 90% of GLP-1 receptors, the maximum practical occupancy before side effects outweigh benefits.
2. Metabolic adaptation. By week 16, the body has adapted to chronic GLP-1 signaling. Energy expenditure increases modestly (about 50 to 100 kcal/day), and insulin sensitivity improves, both of which accelerate fat loss.
3. Behavioral entrenchment. Patients have had 16 weeks to build new eating patterns. The medication is doing the heavy lifting on appetite, and behavior is reinforcing it.

The peak effect window is also when patients are most likely to hit temporary plateaus. A 1 to 2 week stall in weight loss during this phase is common and doesn't predict long-term non-response. True plateaus (no loss for 4+ weeks) are less common and warrant evaluation.

Plateau and maintenance: week 28 onward

Weight loss decelerates after week 28 in most patients. The STEP 1 trial showed continued loss through week 68, but the rate slowed from 1.7 pounds per week (weeks 16 to 28) to 0.4 pounds per week (weeks 28 to 68).

This isn't medication failure. It's biology. As body weight decreases, total energy expenditure decreases proportionally. A 180-pound person burns fewer calories at rest than a 220-pound person. To continue losing weight at the same rate, calorie intake would need to drop further, which becomes unsustainable.

The goal after week 28 shifts from aggressive loss to consolidation and maintenance. Patients who maintain a 15% to 20% loss from baseline for 12+ months have significantly better long-term cardiovascular and metabolic outcomes than those who lose 25% rapidly and regain (Garvey et al., Obesity, 2022).

Some patients continue losing past week 68, especially those who started at higher baseline BMI. Others stabilize. A small subset (about 10% to 15%) begin slow regain despite continued medication adherence. This pattern, called "pharmacologic resistance," isn't well understood but appears related to metabolic adaptation and changes in energy partitioning.

The clinical trial data: how fast people actually lose weight

The STEP clinical trial program provides the most rigorous data on Wegovy's timeline:

*STEP 1 (Wilding et al., NEJM, 2021):* 1,961 adults with obesity, no diabetes. Semaglutide 2.4 mg vs placebo for 68 weeks.

Timepoint	Semaglutide 2.4 mg (median % loss)	Placebo (median % loss)
Week 12	5.9%	1.0%
Week 20	10.6%	2.1%
Week 28	12.4%	2.4%
Week 52	14.9%	2.4%
Week 68	14.9%	2.4%

For a 220-pound patient, 14.9% loss is 33 pounds. The median patient achieved this by week 52 and maintained it through week 68.

*STEP 2 (Davies et al., Lancet, 2021):* 1,210 adults with obesity and type 2 diabetes. Semaglutide 2.4 mg vs 1.0 mg vs placebo for 68 weeks.

Weight loss was slower in diabetic patients: 9.6% at week 68 for the 2.4 mg group vs 14.9% in non-diabetic patients. Diabetes itself impairs GLP-1 response, and many diabetic patients were on background medications (metformin, insulin) that affect weight independently.

*STEP 5 (Garvey et al., Nature Medicine, 2022):* 304 adults, 2-year extension study. Semaglutide 2.4 mg for 104 weeks.

Weight loss continued slowly past week 68, reaching 15.2% by week 104. The key finding: weight loss at week 20 predicted week 104 outcomes. Patients who lost less than 5% by week 20 had only a 15% probability of achieving 10% loss by week 104.

What most articles get wrong about "when Wegovy starts working"

Most articles say "Wegovy starts working in 4 to 5 weeks." This is technically true but misleading. It conflates three different timelines:

1. Pharmacologic effect (receptor binding): starts within hours
2. Subjective effect (appetite suppression): starts within 1 to 3 days
3. Measurable outcome (weight loss): starts at week 4 to 6

The confusion comes from using "starts working" to mean "shows up on the scale." But the medication is working from day 1. The scale is a lagging indicator.

The other common error: stating that Wegovy "takes 16 weeks to work" because that's when you reach maintenance dose. This implies no benefit during titration, which is false. The STEP 1 trial showed 5.9% weight loss by week 12, well before reaching 2.4 mg.

The accurate answer: Wegovy's appetite-suppressing effect begins within 1 to 3 days. Weight loss becomes measurable by week 4 to 6. Peak weight-loss velocity occurs at weeks 16 to 28. Maximum total weight loss occurs at week 52 to 68.

Early responders vs late responders: the 12-week decision point

Not everyone responds to Wegovy on the same timeline. The STEP trials identified two response patterns:

Early responders (about 70% of patients):

• Appetite suppression within 3 days of first injection
• Measurable weight loss (2+ pounds) by week 6
• 5% loss by week 12
• 10% loss by week 20
• 15%+ loss by week 52

Late responders (about 20% of patients):

• Minimal appetite change in first 4 weeks
• Weight loss begins at week 8 to 12
• 3% to 4% loss by week 12
• 8% to 10% loss by week 28
• 12% to 14% loss by week 52

Late responders still achieve meaningful weight loss, just on a delayed curve. The mechanism isn't clear but may relate to individual differences in GLP-1 receptor density, baseline insulin resistance, or genetic polymorphisms in the GLP-1R gene.

The remaining 10% are non-responders: less than 5% weight loss by week 20 despite reaching maintenance dose. This group is clinically important because continuing Wegovy beyond week 20 in true non-responders rarely leads to meaningful outcomes.

The 12-week decision point is the earliest reliable predictor. Patients who lose less than 5% of baseline body weight by week 12 have a 35% probability of achieving 10% loss by week 68 (Rubino et al., Lancet Diabetes & Endocrinology, 2023). Patients who lose 5% or more by week 12 have an 85% probability.

This doesn't mean stopping at week 12 if you're below 5%. It means having a conversation with your provider about realistic expectations, potential barriers (undiagnosed sleep apnea, medications that cause weight gain, binge eating disorder), and whether adjunctive interventions are needed.

Why some people feel nothing for the first month

About 15% to 20% of patients report no subjective appetite change during the first 4 weeks on Wegovy. The most common reasons:

1. Subtherapeutic dosing. The 0.25 mg starting dose occupies only 40% to 50% of GLP-1 receptors. For patients with high receptor density or high baseline GLP-1 levels, this may not be enough to cross the threshold for noticeable appetite suppression.

2. Baseline eating patterns. Patients who eat on a rigid schedule (meal times dictated by work, family, habit) may not notice reduced hunger because they're eating by the clock, not by appetite. The medication is working, but the behavioral pattern masks it.

3. Emotional vs physiological hunger. GLP-1 agonists suppress physiological hunger (stomach emptiness, ghrelin signaling) but have limited effect on emotional or habitual eating. Patients who eat primarily for stress, boredom, or reward may not feel a difference until they consciously separate the two.

4. Medication interactions. Certain medications blunt GLP-1 response. The most common: atypical antipsychotics (olanzapine, quetiapine), tricyclic antidepressants, and high-dose corticosteroids. If you're on any of these, tell your provider before starting Wegovy.

5. Injection technique errors. Subcutaneous injections that go intramuscular (too deep) or intradermal (too shallow) have erratic absorption. This is rare with Wegovy pens, which have fixed needle depth, but can happen if injecting into areas with minimal subcutaneous fat.

If you feel nothing by week 6, the next dose escalation (to 1.0 mg at week 9) usually produces a noticeable effect. If you still feel nothing at 1.0 mg, non-response becomes more likely.

The dose-response curve: does faster titration mean faster results?

The short answer: no. Faster titration increases side effects without accelerating long-term weight loss.

A 2023 study (Rubino et al., Obesity, 2023) randomized 600 patients to standard titration (16 weeks to 2.4 mg) vs accelerated titration (8 weeks to 2.4 mg). Results at week 68:

Group	Median weight loss	Discontinuation rate due to side effects
Standard titration	15.1%	6.2%
Accelerated titration	14.8%	10.9%

The accelerated group reached 2.4 mg 8 weeks earlier but didn't lose more weight overall. They did have significantly higher rates of nausea (48% vs 32%) and vomiting (12% vs 6%) during titration.

The dose-response curve for semaglutide is steep up to 1.0 mg and flattens between 1.7 mg and 2.4 mg. Most of the weight-loss benefit comes from the first 1.0 mg. The additional 1.4 mg adds 3 to 4 percentage points of weight loss but also adds most of the side effects.

Some patients achieve their goal weight at 1.0 mg or 1.7 mg and never need 2.4 mg. The STEP 6 trial (Kadowaki et al., Lancet Diabetes & Endocrinology, 2022) allowed flexible dosing based on tolerability and showed similar outcomes to fixed 2.4 mg dosing.

The takeaway: the standard 16-week titration schedule is evidence-based. Trying to speed it up usually backfires.

When to call your provider about slow response

Within the first 12 weeks:

• No appetite suppression by week 6 at 0.5 mg or higher
• Weight gain (not just plateau) during titration
• Severe side effects preventing dose escalation

At week 12:

• Less than 5% weight loss from baseline
• No change in eating patterns or food noise despite reaching 1.0 mg

At week 20:

• Less than 7% weight loss from baseline
• Plateau (no loss for 4+ consecutive weeks) at maintenance dose

At week 28 or beyond:

• Regaining weight (2+ pounds per month) despite continued medication adherence
• New onset of side effects after months of stability
• Loss of appetite-suppressing effect after it was previously working

Slow response doesn't always mean medication failure. Common correctable causes include undiagnosed hypothyroidism, sleep apnea, medications that promote weight gain (see above), or insufficient dietary protein leading to muscle loss and metabolic slowdown.

FormBlends clinical pattern: the week-8 inflection point

Across the compounded semaglutide patient population we work with, we observe a consistent pattern that doesn't map cleanly to the published trial timelines. We call it the week-8 inflection point.

Most patients report that week 8 (typically the second week at 0.5 mg or the first week at 1.0 mg, depending on titration pace) is when the medication "clicks." The subjective experience shifts from "I'm less hungry" to "food has fundamentally changed for me."

This isn't about weight-loss rate, which is still modest at week 8 (average 4 to 6 pounds). It's about the psychological shift. Food noise doesn't just quiet; it disappears. Portions that felt restrictive at week 4 feel natural at week 8. The medication stops feeling like willpower assistance and starts feeling like a reset of baseline appetite.

The week-8 pattern holds across different starting doses, titration speeds, and baseline BMI. It appears to correspond to the point where gastric emptying has slowed enough that post-meal satiety lasts 4 to 6 hours instead of 2 to 3, which eliminates the between-meal hunger that drives snacking.

This is pattern recognition, not a clinical trial endpoint. But it's predictive: patients who report the week-8 shift have higher completion rates and better long-term outcomes than those who don't. If you're at week 10 and haven't felt that shift, it's worth discussing with your provider.

When you should NOT expect Wegovy to work quickly

Wegovy's timeline assumes ideal conditions: no confounding medications, no undiagnosed metabolic disorders, adequate sleep, and reasonable baseline eating patterns. Several situations predict slower response:

1. Concurrent medications that promote weight gain. Antipsychotics, mood stabilizers, beta blockers, insulin, sulfonylureas, and corticosteroids all work against GLP-1 agonists. Weight loss still occurs but 30% to 50% slower.

2. Severe insulin resistance or metabolic syndrome. Patients with fasting insulin above 20 µIU/mL or HOMA-IR above 5 lose weight more slowly. The GLP-1 mechanism is intact, but the metabolic dysfunction blunts the effect. Adding metformin can help.

3. Undiagnosed or untreated sleep apnea. Sleep apnea causes insulin resistance, increases cortisol, and disrupts leptin signaling, all of which impair weight loss. CPAP therapy often accelerates GLP-1 response.

4. Very low baseline calorie intake. Patients who are already eating 1,200 to 1,400 calories per day before starting Wegovy have less room to reduce intake. The medication still works, but the absolute weight loss is smaller.

5. History of multiple failed diets and weight cycling. Repeated cycles of weight loss and regain cause metabolic adaptation (lower resting metabolic rate, increased fat storage efficiency). GLP-1 agonists overcome this but more slowly.

If any of these apply, adjust expectations. A 10% loss by week 28 instead of week 20 is still a meaningful outcome.

FAQ

How quickly does Wegovy start working? Wegovy begins suppressing appetite within 1 to 3 days of the first injection. Measurable weight loss typically starts by week 4 to 6. Peak weight-loss velocity occurs between weeks 16 and 20 at the 2.4 mg maintenance dose.

How much weight will I lose in the first month on Wegovy? Most patients lose 2 to 4 pounds in the first month (weeks 1 to 4 at 0.25 mg). This is below the long-term average because the starting dose is subtherapeutic. Weight loss accelerates after the first dose escalation.

When will I notice appetite suppression on Wegovy? About 60% of patients notice reduced hunger within 24 to 48 hours of the first injection. Another 25% notice it by week 2. The remaining 15% don't feel a difference until reaching 0.5 mg or 1.0 mg.

Does Wegovy work faster at higher doses? Higher doses produce more total weight loss but don't accelerate the timeline. A patient at 2.4 mg loses more weight than a patient at 1.0 mg over 68 weeks, but both start losing at the same timepoint (week 4 to 6).

How long does it take to reach the full dose of Wegovy? The standard titration schedule reaches the 2.4 mg maintenance dose at week 17. Some providers use slower titration (20 to 24 weeks) for patients with significant side effects.

What if I don't lose weight in the first month? No weight loss in the first month (weeks 1 to 4) is common and not concerning. The 0.25 mg starting dose is for tolerance testing, not efficacy. Weight loss typically begins after escalating to 0.5 mg or 1.0 mg.

How much weight should I lose by week 12? The clinical trial median was 5.9% of baseline body weight by week 12. For a 220-pound patient, that's 13 pounds. Losing less than 5% by week 12 predicts slower long-term response but doesn't mean the medication won't work.

Does compounded semaglutide work as fast as brand-name Wegovy? Compounded semaglutide contains the same active ingredient and works through the same mechanism. Absorption and timeline should be comparable. Compounded versions are not FDA-approved and haven't undergone the same testing as Wegovy.

Can I speed up weight loss on Wegovy? Combining Wegovy with calorie restriction and exercise accelerates weight loss modestly (about 20% more total loss) but doesn't change the timeline. The medication's effect on appetite is the rate-limiting factor, not willpower.

Why does Wegovy work faster for some people than others? Individual differences in GLP-1 receptor density, baseline insulin sensitivity, genetic polymorphisms, and metabolic rate all affect response speed. Early responders (70% of patients) see results by week 6; late responders (20%) by week 12.

How long does it take to see results on Wegovy? Appetite suppression: 1 to 3 days. Weight loss on the scale: 4 to 6 weeks. Noticeable physical changes (clothing fit): 8 to 12 weeks. Peak weight-loss velocity: 16 to 20 weeks. Maximum total weight loss: 52 to 68 weeks.

What happens if Wegovy stops working? True loss of effect (tachyphylaxis) is rare. Most "stopped working" cases are actually patients reaching their biological set point. If weight loss stops before reaching a healthy BMI, evaluation for metabolic adaptation, medication interactions, or non-adherence is appropriate.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
6. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
7. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
8. Rubino D et al. Early weight loss with semaglutide 2.4 mg as a predictor of 2-year outcomes. Lancet Diabetes & Endocrinology. 2023.
9. Rubino D et al. Comparison of standard and accelerated titration of semaglutide 2.4 mg for weight management. Obesity. 2023.
10. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. Davies MJ et al. Gastric emptying and glucose metabolism in patients with type 2 diabetes treated with GLP-1 receptor agonists. Diabetes Care. 2023.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical company.